CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

Some biotechnology companies, such as CRISPR Therapeutics (NASDAQ: CRSP), hope to use gene editing technology to treat, or even cure, diseases that existing drugs cannot. Where to invest $1,000 ...

CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $67.88. The stock has a market capitalization of $3.34 billion, a P/E ratio of -8.85 and a beta of 1.85.

Learn More » CRISPR Therapeutics (NASDAQ: CRSP) is a biotech that generally tackles specialties different from those of Vertex, though it has partnered with Vertex on certain programs.

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on Friday. CRSP has been the subject of a number of other reports.

Crispr Therapeutics, in collaboration with Vertex, pioneered the first CRISPR-based gene therapy, Casgevy, with regulatory approval in multiple countries, poised for strong revenue growth from Q4 ...

CRISPR Therapeutics (NASDAQ: CRSP) made history a year ago this month when the FDA approved Casgevy ® (exagamglogene autotemcel), the CRISPR-edited therapy it co-developed with Vertex ...

Crispr shares are trading higher Thursday after Wolfe Research initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares rise nearly 37% over the past month ...